{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:20:12Z","timestamp":1778037612862,"version":"3.51.4"},"reference-count":13,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"3","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2011]]},"DOI":"10.2133\/dmpk.dmpk-10-rg-112","type":"journal-article","created":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T05:56:50Z","timestamp":1295935010000},"page":"236-241","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetics of Tolterodine in Japanese and Koreans: Physiological and Stochastic Assessment of Ethnic Differences"],"prefix":"10.2133","volume":"26","author":[{"given":"Masayo","family":"Oishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bimal","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/clpt.2009.285","article-title":"Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors","volume":"87","author":"Ichimaru","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0010","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nature04226","article-title":"The International hapMap consortium: A haplotype map of the human genome","volume":"437","year":"2005","journal-title":"Nature"},{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.clpt.6100482","article-title":"Pharmacokinetics\/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations","volume":"84","author":"Myrand","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0020","unstructured":"Pharmaceuticals and Medical Devices agency: Tolterodine Review Report <http:\/\/www.info.pmda.go.jp\/shinyaku\/P200600014\/40007900_21800AMY10088_Q100_1.pdf> <http:\/\/www.info.pmda.go.jp\/shinyaku\/P200600014\/40007900_21800AMY10088_Q101_1.pdf> <http:\/\/www.info.pmda.go.jp\/shinyaku\/P200600014\/40007900_21800AMY10088_Q102_1.pdf> <http:\/\/www.info.pmda.go.jp\/shinyaku\/P200600014\/40007900_21800AMY10088_Q103_1.pdf> <http:\/\/www.info.pmda.go.jp\/shinyaku\/P200600014\/40007900_21800AMY10088_Q104_1.pdf>. (2006)."},{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0025","first-page":"289","article-title":"Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes","volume":"26","author":"Postlind","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0030","doi-asserted-by":"crossref","first-page":"556","DOI":"10.5414\/CPP46556","article-title":"Pharmacokinetic profile of fesoterodine","volume":"46","author":"Malhotra","year":"2008","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0035","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0040","first-page":"229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians","volume":"3","author":"Bradford","year":"2002","journal-title":"Africans and their descendants. Pharmacogenomics"},{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0045","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.11-2-126","article-title":"Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications","volume":"11","author":"Bernard","year":"2006","journal-title":"Oncologist"},{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","article-title":"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity","volume":"5","author":"Ingelman-Sundberg","year":"2005","journal-title":"Pharmacogenomics J."},{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2133\/dmpk.19.83","article-title":"Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1\/ABCB1","volume":"19","author":"Ozawa","year":"2004","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0060","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1124\/dmd.110.033407","article-title":"Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics","volume":"38","author":"Oishi","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-10-RG-112_bb0065","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/ceps.2000.1040","article-title":"Measures of effect size for comparative studies: Applications, interpretations, and limitations","volume":"25","author":"Olejnik","year":"2000","journal-title":"Contemp. Educ. Psychol."}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715305772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715305772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T03:32:50Z","timestamp":1559964770000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715305772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"alternative-id":["S1347436715305772"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.dmpk-10-rg-112","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2011]]}}}